tbuckley/cabot-search huggingface dataset:
Abstract 12804: The Relation between Left Atrial Function and Cardiac Output During Exercise in Left Heart Disease Patients: Insights by Combining Cardiopulmonary Exercise Testing With Stress Echo
Authors: Tadafumi Sugimoto, Francesco Bandera, Greta Generati, Eleonora Alfonzetti, Vincenzo Tufaro, Marco Guazzi
Journal: Circulation (2016)

Background: The hemodynamic response to exercise in left heart disease in relation to left atrial mechanics has never been studied. We aimed at investigating the link between left atrial function and cardiac output (CO) response during exercise in different cardiac disorders. Methods: 73 heart failure with reduced (n=51) and preserved (n=21) ejection fraction, 53 aortic stenosis, 27 primary mitral regurgitation, 14 hypertrophic cardiomyopathy, and 42 control subjects underwent cardiopulmonary exercise testing evaluation combined with Echo-Doppler with assessment of left atrial strain (LAS) and were divided into 4 groups according to LA volume index (LAVI) and LAS at rest. Results: In group D (LAVI ≥34 ml/m 2 , LAS ≤23%, n=80) compared to group A (LAVI &lt;34 ml/m 2 , LAS &gt;23%, n=78) and group C (LAVI ≥34 ml/m 2 , LAS &gt;23%, n=31), peak CO (6.2 ± 2.2 vs 8.5 ± 2.9 and 7.8 ± 2 L/min, P &lt;0.05, respectively) and peak VO 2 (15.3 ± 4.1 vs 18.2 ± 6.3 and 18.1 ± 6.1 ml/kg/min, P &lt;0.05, respectively) were significantly lower and the minute ventilation-carbon dioxide production (VE/VCO 2 ) slope were significantly higher (33.2 ± 9.5 vs 27.1 ±3.7 and 27 ± 3.1, P &lt;0.05, respectively). There were correlation between LAS both at rest and exercise vs peak VO 2 and VE/VCO 2 slope (R=0.41 and R=-0.53 at rest, R=0.44 and R=-0.45 at exercise, P &lt;0.05, respectively, Figure A). In group B (LAVI &lt;34 ml/m 2 , LAS ≤23%, n=19) and D, LAS both at rest and exercise significantly correlated with CO and stroke volume index (R=0.34 and R=0.38 at rest, R=0.35 and R=0.44 at exercise, P &lt;0.05, respectively) and not in Group A and C (Figure B). Conclusions: In left heart disease patients, irrespective of etiology, an impaired LAS performance at rest is associated with a leftward shifted LAS vs CO response during exercise. Among this group of patients LA reservoir function is a key element of increasing CO during exercise.
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials
Authors: Dale N Gerding, Oliver A Cornely, Simon Grill, Hilke Kracker, Anne Claire Marrast, Carl Erik Nord, George H Talbot, Martha Buitrago, Iulian Gheorghe Diaconescu, Claudia Murta de Oliveira, Liliana Preotescu, John Pullman, Thomas J Louie, Mark H Wilcox
Journal: The Lancet Infectious Diseases (2019)
A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Data from the Dose Escalation Part of the Study
Authors: Stephen M Ansell, Robert W. Chen, Andres Forero-Torres, Philippe Armand, Izidore S Lossos, Craig B. Reeder, Andras Strassz, Anne Kerber, Nancy L. Bartlett
Journal: Blood (2017)
Implementing the National Heart, Lung, and Blood Institute’s Strategic Vision in the Division of Cardiovascular Sciences
Authors: David C. Goff, Denis B. Buxton, Gail D. Pearson, Gina S. Wei, Teri E. Gosselin, Ebyan A. Addou, Catherine M. Stoney, Patrice Desvigne-Nickens, Pothur R. Srinivas, Zorina S. Galis, Charlotte Pratt, Brian K. Kit, Christine Maric-Bilkan, Holly L. Nicastro, Renee P. Wong, Vandana Sachdev, Jue Chen, Lawrence Fine, Bishow Adhikari, Sean Altekruse, Sonia Arteaga, Larissa Aviles Santa, Tim Baldwin, Ravi Balijepalli, Rebecca Beer, Carol Blaisdell, Josephine Boyington, Catherine Burke, Kristin Burns, Rebecca Campo, Drew Carlson, Marc Charette, Shu Hui Chen, Sean Coady, Lawton Cooper, Narasimhan Danthi, Gaya Dowling, Ray Ebert, Paula Einhorn, Jerry Fleg, Yunling Gao, Nancy Geller, Matthew Gillam, Kathy Green, Maya Harris, Ahmed Hasan, Lucy Hsu, Alice Hurtado de Mendoza, Pamela James, Erin Iturriaga, Cashell Jaquish, Shari Ludlam, Katherine Kavounis, Fassil Ketema, Jonathan Kaltman, Dong-Yun Kim, Andrei Kindzelski, Ruth Kirby, John Kunz, Eric Leifer, Huiqing Li, Lijuan Liu, Martha Lundberg, James Luo, Marissa Miller, Cheryl Nelson, Margaret Ochocinska, Michelle Olive, Jean Olson, Anne O’Malley, Stavroula Osganian, Young Oh, Melissa Green Parker, Mona Puggal, Kevin Purkiser, Nicole Redmond, Diane Reid, Jared Reis, Yves Rosenberg, Charlene Schramm, Lisa Schwartz-Longacre, Jane Scott, Scarlet Shi, Phyliss Sholinsky, Lorraine Silsbee, Joni Snyder, George Sopko, Dennis Stanley, Wendy Taddei-Peters, Perdita Taylor-Zapata, Emily Tinsley, Olga Tjurmina, Eser Tolunay, Michael Twery, Myron Waclawiw, Jenelle Walker, Barbara Wells, Michael Wolz, Jacqueline Wright, Colin Wu, Ye Yan, Song Yang
Journal: Circulation Research (2019)

As we commemorate the 70
Hemolysis and Tricuspid Regurgitation Jet Velocity Predict Mortality in Patients with Sickle Cell Disease
Authors: Payal Shah, Adam Bush, Silvie Suriany, Honglei Liu, Henry J Forman, Patjanaporn Chalacheva, Wanwara Thuptimdang, John Sunwoo, Saranya Veluswamy, Christopher Clement Denton, Maha Khaleel, Roberta Miyeko Kato, Ajay Perumbeti, Richard Sposto, Michael Khoo, Thomas D. Coates, John C Wood, Jon A Detterich
Journal: Blood (2018)
Abstract MP53: 1,5-anhydroglucitol to Identify Older Adults with Diabetes at Risk of Hospitalization and All-cause Mortality
Authors: Bethany Warren, Andreea Rawlings, A. Richey Sharrett, Josef Coresh, Anna Kottgen, Elizabeth Selvin
Journal: Circulation (2018)

Introduction: Older adults with diabetes have variable prognosis. There is critical need to improve risk stratification among this population to understand who is most likely to experience adverse outcomes. Low 1,5-anhydroglucitol (1,5-AG) is a biomarker of glycemic variability and has demonstrated value for identification of middle-aged adults with diabetes at risk for major clinical outcomes. Total hospitalizations are a useful summary measure of poor health outcomes. It is unknown whether 1,5-AG can identify older adults at risk for hospitalizations and all-cause mortality. Methods: We included 2,061 participants from the Atherosclerosis Risk in Communities (ARIC) Study with diagnosed diabetes who attended the 2011-2013 visit. We dichotomized 1,5-AG (≥6μg/mL; &lt;6μg/mL) and followed participants until December 31, 2015. We examined the associations of 1,5-AG with total and diabetes-related hospitalizations using negative binomial regression and all-cause mortality using Cox regression. Results: Participants ranged in age from 67-90 years, 57% were female, 30% were black, and 17% had 1,5-AG &lt;6μg/mL. Median HbA1c was 6.2% in those with 1,5-AG ≥6μg/mL and 7.8% in persons with 1,5-AG &lt;6μg/mL. During a median of 3.6 years of follow-up, there were 2,813 hospitalizations (1,689 diabetes-related) and 247 deaths. Compared to 1,5-AG ≥6μg/mL, individuals with 1,5-AG &lt;6μg/mL had a significantly higher risk of hospitalizations, diabetes-related hospitalizations, and death ( Table ). After adjustment for diabetes medication use or HbA1c, associations with hospitalizations were attenuated and non-significant, while the relationship with all-cause mortality remained. Conclusion: Among older adults with diagnosed diabetes, glycemic variability may be an important risk factor for major short-term complications.
Cholecystectomy reduced major complications vs catheter drainage in high-risk patients with acute cholecystitis
Authors: Joseph F. Rappold
Journal: Annals of Internal Medicine (2019)

Source Citation Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): multicentre randomised clinical trial. BMJ. 2018;363:k3965. 30297544
Ethics of Human Genome Editing
Authors: Barry S. Coller
Journal: Annual Review of Medicine (2019)

Advances in human genome editing, in particular the development of the clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 method, have led to increasing concerns about the ethics of editing the human genome. In response, the US National Academy of Sciences and the National Academy of Medicine constituted a multidisciplinary, international committee to review the current status and make recommendations. I was a member of that committee, and the core of this review reflects the committee's conclusions. The committee's report, issued in February 2017, recommends the application of current ethical and regulatory standards for gene therapy to somatic (nonheritable) human genome editing. It also recommends allowing experimental germline genome editing to proceed if ( a) it is restricted to preventing transmission of a serious disease or condition, ( b) the edit is a modification to a common DNA sequence known not to be associated with disease, and ( c) the research is conducted under a stringent set of ethical and regulatory requirements. Crossing the so-called red line of germline genome editing raises important bioethical issues, most importantly, serious concern about the potential negative impact on individuals with disabilities. This review highlights some of the major ethical considerations in human genome editing in light of the report's recommendations.
We need fewer leaders and more followers
Authors: Kamran Abbasi
Journal: BMJ (2019)

Clinical leadership may be a dangerous concept. What does it mean? How do we know when we’ve got there? Is it mere puppetry in politicians’ interfering hands? Whatever the answer to these questions, the consensus is that clinical leadership is a good thing and we’ve been right to strive for decades to make it happen. But if everybody leads, who follows? “Leadership quangos abound,” says Partha Kar, a clinical leader himself, “courses are drip fed into email boxes, and conferences keep springing up” (doi:10.1136/bmj.l248). Any leader is only as good as the people who follow, so where are the quangos, emails, …
Endoscopic management of biliary leaks: a systematic review with meta-analysis
Authors: Kenny Vlaemynck, Lies Lahousse, Aude Vanlander, Hubert Piessevaux, Pieter Hindryckx
Journal: Endoscopy (2019)

Abstract Background The first-line approach to the treatment of biliary leaks is endoscopic retrograde cholangiopancreatography. A variety of techniques can be used, including sphincterotomy, stenting, a combination of both techniques, or nasobiliary drainage. We performed a systematic review with meta-analysis to define the optimal strategy. Methods We searched MEDLINE/PubMed, EMBASE, CENTRAL, Scopus, Google Scholar, and Web of Science until January 2018 for randomized clinical trials, case-control studies, and prospective cohort studies. Data on procedure, success, and complication rate were extracted. Risk of bias was assessed. A network meta-analysis was performed to compare sphincterotomy alone vs. stenting alone vs. combination treatment. Stenting was further stratified into leak-bridging and short stenting. Results 11 studies out of 5085 references were included. Compared with sphincterotomy alone, the combination of sphincterotomy with leak-bridging stenting had the highest success rate (risk ratio [RR] 1.15, 95 % confidence interval [CI] 0.97 – 1.50), followed by leak-bridging stenting alone (RR 1.10, 95 %CI 0.84 – 1.44). For nonbridgeable leaks, stenting alone had a higher success rate than sphincterotomy alone (RR 1.07, 95 %CI 0.72 – 1.40). The combination of short stents with sphincterotomy had no added benefit (RR 0.94, 95 %CI 0.49 – 1.29). Overall quality of the included studies was considered to be moderate. Conclusions We recommend sphincterotomy with stenting if the biliary leak can be bridged. If not, stenting alone with a short stent may be preferred in order to avoid sphincterotomy-related complications. More and larger studies are needed to confirm these findings.
Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation
Authors: Sergio Martinez-Høyer, Angela Mo, Deborah Deng, Jihong Jiang, Rod Docking, Jenny Li, Simon Chan, Patricia Umlandt, Megan Fuller, Martin Jädersten, Eva Hellström-Lindberg, Uwe Platzbecker, Jeremy Parker, Aly Karsan
Journal: Blood (2018)
Just-in-Time Instructions for Layperson Tourniquet Application
Authors: Craig A. Goolsby, Arthur L. Kellermann, Thomas D. Kirsch
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract A30: Preclinical study of a combination of mocetinostat (HDAC inhibitor) and 5-AZA-dC (decitabine) in chondrosarcoma
Authors: Tahir N. Sheikh, Parag Patwardhan, Gary K. Schwartz
Journal: Clinical Cancer Research (2018)

Abstract Chondrosarcomas are the second most frequently occurring type of bone malignancy, and account for approximately 25% of all bone sarcomas. They are often highly aggressive neoplasms that rapidly progress and eventually recur and give distant metastases. They are largely considered to be resistant to conventional chemotherapy and radiotherapy. Previous reports have shown that the interaction of DNA methylation and histone modification regulates gene expression, and targeting these mechanisms could be a potentially novel approach to treat cancer. In the present study, we hypothesized that concurrent inhibition of histone acetylation and DNA methylation could result in decreased viability of chondrosarcoma cells. To test this, we used a panel of chondrosarcoma cell lines including IDH wild type (CH2879), IDH1 mutant (JJ012), and IDH2 mutant (SW1353) cell line. Results from our in vitro proliferation assay showed that combination of sub-IC50 concentrations of the DNA methyltransferase (DNMT) inhibitor decitabine (5-AZA-dC) and a spectrum-selective class I and IV histone deacetylase (HDAC) inhibitor mocetinostat (MGCD0103) resulted in decreased cell viability, which appears to be at least additive, in all the three chondrosarcoma cell lines when compared to either of the two drugs alone. Western blot analysis showed induction of cleaved Poly-ADP Ribose Polymerase (PARP) as well as cleaved caspase 3, known markers of apoptosis. Consistent with augmented DNA damage, combination of decitabine and MG103 markedly increased the levels of phospho-H2AX, a DNA damage marker, and proapoptotic BH3-only proteins such as Bim. Combination treatment also resulted in increased induction of histone acetylation (AcH3 and AcH4) and increased expression of E-cadherin, an important tumor suppressor gene. Cell cycle analysis showed induction of sub-G1 population phase in combination treatment. Previous reports have shown that CpG methylation is a critical event in transcriptional repression of hypermethylated genes in cancer. To this end, we show that combination treatment with mocetinostat and 5-AZA-dC results in downregulation of (H3K9) methylation. Taken together, our data strongly suggest that combination treatment with mocetinostat and decitabine is a novel treatment approach and merits evaluation in the treatment of chondrosarcoma. Citation Format: Tahir N. Sheikh, Parag Patwardhan, Gary K. Schwartz. Preclinical study of a combination of mocetinostat (HDAC inhibitor) and 5-AZA-dC (decitabine) in chondrosarcoma [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr A30.
Cardiovascular Risk Factor Burden in People With Incident Type 2 Diabetes in the U.S. Receiving Antidiabetic and Cardioprotective Therapies
Authors: Olga Montvida, Xiaoling Cai, Sanjoy K. Paul
Journal: Diabetes Care (2019)

Individualized treatment of patients with diabetes requires detailed evaluation of risk factor dynamics at the population level. This study evaluated the persistent glycemic and cardiovascular (CV) risk factor burden over 2 years after treatment intensification (TI).From U.S. Centricity Electronic Medical Records, 276,884 patients with incident type 2 diabetes who intensified metformin were selected. Systolic blood pressure (SBP) ≥130/140 mmHg and LDL ≥70/100 mg/dL were defined as uncontrolled for those with/without a history of CV disease at TI. Triglycerides ≥150 mg/dL and HbA1c ≥7.5% (58 mmol/mol) were defined as uncontrolled. Longitudinal measures over 2 years after TI were used to define risk factor burden.With 3.7 years' mean follow-up, patients were 59 years; 70% were obese; 22% had a history of CV disease; 60, 30, 50, and 48% had uncontrolled HbA1c, SBP, LDL, and triglycerides, respectively, at TI; and 81% and 69% were receiving antihypertensive and lipid-modifying therapies, respectively. The proportion of patients with consistently uncontrolled HbA1c increased from 31% in 2005 to 41% in 2014. Among those on lipid-modifying drugs, 41% and 37% had consistently high LDL and triglycerides over 2 years, respectively. Being on antihypertensive therapies, 29% had consistently uncontrolled SBP. Among patients receiving cardioprotective therapies, 63% failed to achieve control in HbA1c + LDL, 57% in HbA1c + SBP, 55% in LDL + SBP, and 63% in HbA1c + triglycerides over 2 years after TI.Among patients on multiple therapies for risk factor control, more than one-third had uncontrolled HbA1c, lipid, and SBP levels, and more than one-half had two CV risk factors that were simultaneously uncontrolled after TI.
John Grimley Evans
Authors: Piers S Grimley Evans
Journal: BMJ (2019)

Professor Sir John Grimley Evans broke ground in medicine for the elderly in the later 20th century. His greatest achievement was driving the integration of older adults into acute general hospital care. At Newcastle upon Tyne from 1971 and Oxford from 1985, he helped end the routine dispatching of older patients to substandard care at separate facilities. 

Combining an enthusiasm for epidemiology and clinical medicine, he also broached key research fields, overseeing large community based population studies on strokes and hip fractures.

Later in his career he further contributed to the profession by chairing national and international committees and serving as vice president of the Royal College of Physicians.

In 1988-95 he edited the British Geriatric Society’s Age and Ageing . Producing the journal from his front room, he established it as a respected academic publication in a two person team with his wife, Corinne.

He won an open scholarship in natural sciences at St John’s College, Cambridge, and completed his medical degree at Oxford. A series of happy accidents then proved the ideal …
Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study
Authors: Claudia A.M. Stege, Kazem Nasserinejad, Mark-David Levin, Saskia K. Klein, Esther de Waal, Corien Eeltink, Charlotte L.B.M. Korst, Paula F Ypma, Amanda C. Dijk, Matthijs Westerman, Wendy Deenik, Bea Tanis, Monique C Minnema, Henk M.W. Verheul, Birgit I. Lissenberg-Witte, Niels WCJ van de Donk, Pieter Sonneveld, Sonja Zweegman
Journal: Blood (2018)
Multi-Dimensional T-Cell Functional Analysis by Spectral Flow Cytometry as a Tool to Dissect Endotypes in Allergic Disease.
Authors: Alberta GA. Paul, Jill Glesner, Josephine Lannigan, Lyndsey M. Muehling, Jacob D. Eccles, Paul W. Wright, Anna Pomes, Judith A. Woodfolk
Journal: Journal of Allergy and Clinical Immunology (2019)
Hematopoietic Stem Cell Transplantation in Children with Refractory Langerhans Cell Histiocytosis
Authors: Kazuko Kudo, Miho Maeda, Nobuhiro Suzuki, Hirokazu Kanegane, Shouichi Ohga, Eiichi Ishii, Yoko Shioda, Toshihiko Imamura, Shinsaku Imashuku, Yukiko Tsunematsu, Mikiya Endo, Akira Shimada, Yuuki Koga, Yoshiko Hashii, Jiro Inagaki, Masami Inoue, Ken Tabuchi, Akira Morimoto
Journal: Blood (2018)
Chemical Wave Transmission in Nerve.
Authors: A. V. Hill
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Spontaneous Regression of Clinically Indolent Lymphomas Revealed by 18F-FDG PET/CT
Authors: Qingqing Pan, Yaping Luo, Xinxin Cao, Yan Zhang, Fang Li
Journal: Clinical Nuclear Medicine (2019)

A 48-year-old man and a 55-year-old woman, who were diagnosed with follicular lymphoma and small B lymphocytic cell lymphoma, respectively, underwent initial "watch-and-wait" approach against lymphoma. The initial F-FDG PET/CT of both patients showed multiple FDG-avid lymph nodes in the neck, mediastinum, abdomen, and inguinal regions. During their active surveillance, the follow-up PET/CT of both patients revealed spontaneous regression of lymphoma.